Our top pick for
Anika Therapeutics, Inc is a biotechnology business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 154 staff and has a trailing 12-month revenue of around USD$125.5 million.
|52-week range||USD$22.01 - USD$75.715|
|50-day moving average||USD$36.5197|
|200-day moving average||USD$34.9119|
|Wall St. target price||USD$51|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.793|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Anika Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Anika Therapeutics shares trade at around 49x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1868. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$32.4 million.
The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$125.5 million|
|Operating margin TTM||18.26%|
|Gross profit TTM||USD$85.9 million|
|Return on assets TTM||3.94%|
|Return on equity TTM||4.2%|
|Market capitalisation||USD$537.3 million|
TTM: trailing 12 months
There are currently 1.8 million Anika Therapeutics shares held short by investors – that's known as Anika Therapeutics's "short interest". This figure is 11.8% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting Anika Therapeutics shares can be evaluated.
Anika Therapeutics's "short interest ratio" (SIR) is the quantity of Anika Therapeutics shares currently shorted divided by the average quantity of Anika Therapeutics shares traded daily (recently around 136994.46550417). Anika Therapeutics's SIR currently stands at 13.19. In other words for every 100,000 Anika Therapeutics shares traded daily on the market, roughly 13190 shares are currently held short.
However Anika Therapeutics's short interest can also be evaluated against the total number of Anika Therapeutics shares, or, against the total number of tradable Anika Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anika Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Anika Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.151% of the tradable shares (for every 100,000 tradable Anika Therapeutics shares, roughly 151 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Anika Therapeutics.
Find out more about how you can short Anika Therapeutics stock.
We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $22.01 up to $75.715. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 1.1048. This would suggest that Anika Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company manufactures and distributes therapeutic products based on its hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, ORTHOVISC-T, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; and Tactoset, a synthetic, biocompatible hyaluronic acid-based bone graft substitute.The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; HYALOGRAN, HYAFF fibers used for orthopedic and trauma reconstructive surgical procedures; HYALOGLIDE used for the treatment of tendon, peripheral nerve, and articular surgeries; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.